by spring (24.1%), fall (22.8%), and winter (20.3%). The clinical and laboratory characteristics at presentation are shown in Table 1. Muscle biopsy was performed in 93% of patients. Notably, patients with swallowing difficulties had more commonly had Raynaud phenomenon (RR 3.7 [95% CI 1.4–9.4], p<0.008).

Conclusions: The averaged 12-year annual incidence of IM in the population under study was 9.4 ([95% CI 7.5–11.8] per 10^6 adults.

References:

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.2688

Spondyloarthritis - treatment

**AB0683** TROUGH INFlixIMAB LEVELS AND ANTI-INFlixIMAB ANTIBODIES IN SPONDYLOARTHRITIS PATIENTS ON TREATMENT WITH LOW DOSE INFlixIMAB: A SINGLE CENTRE CROSS-SECTIONAL STUDY

A. Patil 1, S.K. Upadhyaya 1, R. Dawar 2, B. Vaishnav 1, N. Dadhaniya 1, S.J. Gupta 1, R. Handa 1, 1Rheumatology; 2Microbiology, Indraprastha Apollo Hospitals, Delhi, India

Background: Infliximab (IFx) is an anti-TNF chimeric, monoclonal antibody approved for use in refractory spondyloarthritis (SpA). Studies done in patients with rheumatoid arthritis and Inflammatory bowel disease have demonstrated the clinical utility of the measurement of serum trough IFx and antibodies to IFx (ATI). In India, many centres including ours use IFx at lower doses of 3–5 mg/kg and on demand IFx treatment without the use of the loading dose IFx in SpA patients. Data on the utility of measuring trough IFx and ATI levels and their correlation with disease activity in such group of patients is lacking.

Objectives: To evaluate the co-relation between trough Infliximab levels and disease activity measures, viz ASDAS ESR and ASDAS CRP in SpA patients on low dose IFx therapy

To compare the mean ASDAS-ESR/CRP scores between ATI positive and ATI negative patients

Methods: Thirty-nine adult spondyloarthrtitis patients in the age group of 18–70 years, meeting the ASAAS classification criteria for peripheral and/or axial spondyloarthritis were recruited into the study. The inclusion criteria required the patients to have had received three or more infusions of IFx at 3–5 mg/kg/dose over the past 6 to 9 months. Blood samples were collected between two to three months after the previous IFx infusion for the measurement of the ATI and the trough IFx levels using the Matriks Biotech Shikari Q-ATI ELISA and Q-IFLIX ELISA kits respectively. At the same time, disease activity of the patients was quantitated using ASDAS ESR and ASDAS CRP scores.

Correlation between the ASDAS scores and the trough IFx levels was analysed by Pearson’s product moment correlation assay. The difference in mean trough IFx and ASDAS scores between the ATI positive and ATI negative patients were assessed using Welch two sample t-test.

Results: There was a moderately significant negative correlation between the trough IFx levels and the ASDAS ESR (r = −0.69, p<0.001), ASDAS CRP (r = −0.67, p<0.001) (Fig 1). ATi positive patients in comparison to ATi negative, had significantly higher ASDAS ESR and ASDAS CRP scores (Table 1).

Table 1. Table showing differences in ASDAS scores between ATI positive and negative patients

<table>
<thead>
<tr>
<th>ATI +ve patients</th>
<th>ATI -ve patients</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean ASDAS ESR</td>
<td>3.13</td>
<td>1.56</td>
</tr>
<tr>
<td>Mean ASDAS CRP</td>
<td>3.06</td>
<td>1.45</td>
</tr>
</tbody>
</table>

Conclusions: SpA patients from India on low dose, on demand IFx therapy, have both the trough IFx and ATI correlate significantly with the measures of disease activity. Therefore, these may be used in addition to clinical activity scores for a more cost effective on demand IFx therapy in SpA patients, especially in an expense constrained country like India.

References:

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.2690

**AB0684** CLINICAL RESPONSE AND RADIOGRAPHIC PROGRESSION IN ANKYLOSING SPONDYLITIS PATIENTS UNDER ANTI-TNF THERAPY: IMPACT OF HIP INVOLVEMENT

A.Y. Shimabuco 1, F.M. Milanez 1, J.C.B. Moraes 1, G.V. Perico 2, C.R. Gonçalves 1, M.G. Waisberg 1, P.D. Sampaio-barros 1, C.G.S. Saad 1

1Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo; 2Unidade Radiológica Cricúmia, Cricúma, Brazil

Background: Hip involvement is considered an important prognostic factor associated with radiographic progression in ankylosing spondylitis (AS) patients. However, there are no studies regarding hip involvement impact on clinical response and radiographic progression in AS patients under anti-TNF therapy.

Objectives: Compare clinical and radiographic progression in AS patients receiving anti-TNF therapy with and without moderate-severe hip involvement.

Methods: Forty-seven AS patients referred to receive anti-TNF treatment were included and classified according to baseline hip involvement based on Bath Ankylosing Spondylitis Radiology Hip Index (BASRI-Hip): none-minimal hip disease (hip grade <3) or moderate-severe disease (hip grade ≥3). Demographic data, presence of HLA-B27, extra-articular involvement, DMARD and NSAID use, and laboratory disease activity and damage parameters (BASDAI, BASMI, BASFI, ASQoL, mSASSS and inflammatory markers) were assessed at baseline and two years after anti-TNF treatment.

Results: Thirty-four (72.3%) patients were classified as none-minimal hip disease and 13 (27.7%) as moderate-severe hip involvement. Both groups were similar at baseline concerning age, HLA-B27, extra-articular involvement and comodication use. Laboratory markers (ESR, CRP) and disease parameters (BASDAI, BASFI, ASQoL, mSASSS and inflammatory markers) showed no difference at baseline. Moderate-severe group had longer disease (10.0±7.6 vs. 14.9±8.6, P=0.002, years), higher BASDAI (3.8±2.4 vs. 6.5±2.5, P=0.002) and lower ASQoL (13.7±4.4 vs. 9.9±4.9, P=0.007). After two-years of anti-TNF therapy, both groups presented similar BASDAI response (delta BASDAI, p=0.134; final BASDAI, p=0.324) and an increase in mSASSS [no-minimal involvement: 13.6±18.3 vs. 16.1±19.4, P=0.001; moderate-severe involvement: 21.7±19.9 vs. 28.6±18.5, P=0.003]. At final evaluation patients with moderate-severe hip involvement presented higher mSASSS (28.6±18.5 vs. 16.1±19.4, P=0.02), despite similar delta BASDAI and final BASDAI.

Conclusions: Our study provides evidence that hip involvement did not impact on clinical response in AS patients under anti-TNF therapy but may have an effect on radiographic progression of these patients.